Inclusion Criteria:  Age between 18 and 75 years inclusive; Histologically or cytologically confirmed advanced malignant solid tumors, eligible patients should be either refractory or intolerant to all available therapies known to confer a clinical benefit as determined by the investigator, except for primary hepatic carcinoma; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; Life expectancy ≥ 3 months; Adequate hematologic, hepatic and renal function; Participant willing to agree to not father a child/become pregnant and comply with effective contraception criteria; Provision of signed and dated, written informed consent prior to any study-specific evaluation.  Exclusion Criteria:  Previous treatment with any SHP2 inhibitors; Spinal cord compression, meningeal metastases or brain metastases unless asymptomatic, stable and not requiring steroids for at least 2 weeks prior to start of study treatment; Life-threatening autoimmune disease or autoimmune disorder with long-term steroid treatment; Active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) and treponema pallidum (TP); Patients who have impaired cardiac function or clinically significant cardiac diseases; Active, clinically significant interstitial lung disease or pneumonitis; Females who are pregnant or breastfeeding; Judgment by the investigator that the patient should not participate in the study.